In particular, preclinical studies should assess gastric emptying and conditioned taste aversion to better understand potential physiological effects and safety implications
Also, it is important to consider its long-term benefits and potential cost savings associated with improved health outcomes
[iii] Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D
59 Small molecule GLP-1RA in preclinical trials MLX-7005 MLX-7005 is a highly potent, oral small-molecule GLP-1 receptor agonist (GLP-1RA) that robustly activates the GLP-1 receptor cAMP signaling pathway without measurable -arrestin recruitment